ePRO provider Symfo will now offer technology transfer capabilities with its new product Artist. This new product is a user-friendly tool that allows customers to build and deploy their own ePRO studies on demand.
Users have the option to start with Symfo's full-service offering and migrate to Artist when ready, or to begin using it from the very first study. Artist was designed with simplicity in mind to benefit Data Managers, CRAs, and Clinical Assistants. Programming skills are not necessary and a basic knowledge of the MS Office suite is sufficient, according to the company.
Artist may be accessed locally or through an Internet connection. Designers start by defining the general parameters such as name and languages of the study using a configuration panel. The next step is to design each PDA screen with edit checks and logic. Artist offers a drag and drop interface that is intended to make this step straightforward, including importing translations if necessary. Once all designing is completed, users have the ability to test the application in a built-in emulator. The application is then installed on the PDAs and will launch automatically.
Artist is available on a subscription pay-as-you-go basis, either as a stand-alone product or as part of a turn-key bundled package. Visit the company's Web site for more information on this product, www.symfo.com.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.